Bayer AG's First Quarter Fiscal 2025 Overview

Bayer AG announced on Tuesday that its sales for the first quarter of fiscal 2025 remained stable at €13.7 billion, showing no significant change from the same period in 2024. This performance comes at a time when the company is navigating through a challenging fiscal year.

Financial Performance Highlights

Despite the steady sales, the company witnessed a sharp 35.1% decline in net income to €1.3 billion on an annual basis. Earnings per share also took a hit, dropping by 35.3% to €1.32. However, Bayer remains optimistic, reaffirming its currency-adjusted guidance for 2025 and anticipating sales growth at the upper end of the range provided in the Annual Report 2024.

Leadership's Perspective

"Our first quarter puts us in a good spot to deliver in a challenging and important year for the company," stated CEO Bill Anderson. He emphasized the growth within the Pharmaceuticals Division as a positive indicator of the company's operational efficiency. "That is an encouraging sign that our operating model is helping teams do more with less. We're confident in the momentum of our launches and the fundamentals of our business," Anderson added.